GenSight Biologics Burns Cash as Early Access Programs Fuel Runway Extension
Event summary
- GenSight Biologics' cash position dropped to €1.7M as of June 30, 2026, from €3.2M three months prior.
- Collected €6.8M in early access program proceeds during H1 2026, with €4.3M coming in Q2 alone.
- Phase III RECOVER study preparation and manufacturing process optimization continue at Catalent.
- Heights Capital requested deferral of June 2026 convertible bond amortization to December 2027.
The big picture
GenSight's strategic focus on early access programs as a financial lifeline reflects broader biotech trends of leveraging pre-approval treatments to extend runway. The company's ability to manage manufacturing scale-up and regulatory obligations will determine its path to commercialization for GS010/LUMEVOQ® in Leber Hereditary Optic Neuropathy.
What we're watching
- Cash Flow Dynamics
- Whether early access program revenues can sustain operations through 2026, excluding Phase III study costs.
- Manufacturing Readiness
- The pace at which Catalent completes technology transfer and begins producing batches for the RECOVER study.
- Regulatory Compliance
- How the 25-35% rebate requirement on French early access proceeds will impact 2027 cash flows.